LYNBROOK, N.Y., July 12 /PRNewswire-FirstCall/ —
BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing
first in class collagenase-based products, today announced that its
strategic partner Auxilium Pharmaceuticals, Inc. has provided an
update on XIAFLEX, its injectable collagenase product currently
marketed in the U.S. for the treatment of Dupuytren’s
Auxilium announced that XIAFLEX sales to physicians were $2.0 million for the second quarter of
2010. Auxilium also updated the following leading indicators which
it tracks in connection with the XIAFLEX launch. As of June 30, 2010:
- 1,629 physicians and 1,122 sites have completed the training
and enrollment process, compared to 1,421 and 962, respectively, at
the end of May.
- A total of 1,458 insurance verification requests and 543
referrals to specialty pharmacies have been received by the
Auxilium call center, up from 886 and 336, respectively, at the end
- The number of cumulative, unique sites ordering XIAFLEX for the
first time is 241 compared to 138 sites at the end of May.
- Auxilium believes that approximately 90% of insured lives in
the U.S. have access to XIAFLEX.
In addition, Auxilium announced that it held its end of phase II
meeting with the U.S. Food and Drug Administration in late June 2010 regarding development of XIAFLEX
for the treatment of Peyronie’s disease and that, as a result,
Auxilium is reaffirming its plan to initiate phase III pivotal
trials by the end of 2010.